Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BM32 dosing schedules for grass pollen allergy
NCT02643641Phase 2Completed
- Sponsor
- Biomay AG
- Start
- Jan 2016
- Primary completion
- Oct 2016
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of BM32 in seasonal allergic rhinitis (SAR), sponsored by Biomay AG. Started Jan 2016; status: completed.
02
Drugs
BM32
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on NCT02643641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02643641.